ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 530,72
0,00%
Dow Jones
39 164,06
0,09%
DAX
18 210,55
0,26%
Brent Oil
85,695
0,33%
Bitcoin
61 505,08
-0,17%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Nurix Therapeutics Inc (NRIX)

  7. Nurix Therapeutics Inc (NRIX) Actualités

NRIX

Nurix Therapeutics (NRIX)

Nurix Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NRIX
DateHeureSourceTitreSymboleSociété
17/06/202413h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRIXNurix Therapeutics Inc
16/06/202411h30GlobeNewswire Inc.Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)NASDAQ:NRIXNurix Therapeutics Inc
14/06/202400h39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRIXNurix Therapeutics Inc
11/06/202422h06Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:NRIXNurix Therapeutics Inc
10/06/202413h00GlobeNewswire Inc.Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024)NASDAQ:NRIXNurix Therapeutics Inc
03/06/202422h58Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NRIXNurix Therapeutics Inc
29/05/202413h00GlobeNewswire Inc.Nurix Therapeutics to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:NRIXNurix Therapeutics Inc
28/05/202413h00GlobeNewswire Inc.Nurix Therapeutics Appoints Paula G. O’Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical OfficerNASDAQ:NRIXNurix Therapeutics Inc
20/05/202422h00GlobeNewswire Inc.Nurix Therapeutics Announces Board Chair TransitionNASDAQ:NRIXNurix Therapeutics Inc
14/05/202416h00GlobeNewswire Inc.Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)NASDAQ:NRIXNurix Therapeutics Inc
07/05/202413h00GlobeNewswire Inc.Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare ConferenceNASDAQ:NRIXNurix Therapeutics Inc
17/04/202400h21GlobeNewswire Inc.Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:NRIXNurix Therapeutics Inc
12/04/202405h38GlobeNewswire Inc.Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public OfferingNASDAQ:NRIXNurix Therapeutics Inc
11/04/202422h00GlobeNewswire Inc.Nurix Therapeutics Announces Proposed Public OfferingNASDAQ:NRIXNurix Therapeutics Inc
10/04/202413h00GlobeNewswire Inc.Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate UpdateNASDAQ:NRIXNurix Therapeutics Inc
09/04/202419h15GlobeNewswire Inc.Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell MalignanciesNASDAQ:NRIXNurix Therapeutics Inc
09/04/202413h00GlobeNewswire Inc.Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6NASDAQ:NRIXNurix Therapeutics Inc
03/04/202413h00GlobeNewswire Inc.Nurix Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:NRIXNurix Therapeutics Inc
02/04/202413h00GlobeNewswire Inc.Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead SciencesNASDAQ:NRIXNurix Therapeutics Inc
25/03/202412h00GlobeNewswire Inc.Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)NASDAQ:NRIXNurix Therapeutics Inc
20/03/202414h40GlobeNewswire Inc.Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) MeetingNASDAQ:NRIXNurix Therapeutics Inc
11/03/202412h00GlobeNewswire Inc.Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 TrialNASDAQ:NRIXNurix Therapeutics Inc
05/03/202422h30GlobeNewswire Inc.Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual MeetingNASDAQ:NRIXNurix Therapeutics Inc
15/02/202422h51Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NRIXNurix Therapeutics Inc
15/02/202422h00GlobeNewswire Inc.Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate UpdateNASDAQ:NRIXNurix Therapeutics Inc
14/02/202414h51Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NRIXNurix Therapeutics Inc
01/02/202422h01GlobeNewswire Inc.Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 DegraderNASDAQ:NRIXNurix Therapeutics Inc
29/01/202422h00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:NRIXNurix Therapeutics Inc
16/01/202422h48Dow Jones NewsNurix Therapeutics Gets FDA Fast-Track Designation for NX-5948NASDAQ:NRIXNurix Therapeutics Inc
16/01/202422h01GlobeNewswire Inc.Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLLNASDAQ:NRIXNurix Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NRIX

Dernières Valeurs Consultées

EU
ASM
ASM International NV
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés